- Home
- RVSB vs IKNA Comparison
RVSB vs IKNA Comparison
Compare RVSB & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVSB
- IKNA
- Stock Information
- Founded
- RVSB 1923
- IKNA 2016
- Country
- RVSB United States
- IKNA United States
- Employees
- RVSB N/A
- IKNA N/A
- Industry
- RVSB Savings Institutions
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- RVSB Finance
- IKNA Health Care
- Exchange
- RVSB Nasdaq
- IKNA Nasdaq
- Market Cap
- RVSB 119.6M
- IKNA 63.7M
- IPO Year
- RVSB 1993
- IKNA 2021
- Fundamental
- Price
- RVSB $5.46
- IKNA $1.43
- Analyst Decision
- RVSB Buy
- IKNA Strong Buy
- Analyst Count
- RVSB 1
- IKNA 1
- Target Price
- RVSB $7.00
- IKNA $4.00
- AVG Volume (30 Days)
- RVSB 258.8K
- IKNA 105.8K
- Earning Date
- RVSB 07-24-2025
- IKNA 08-07-2025
- Dividend Yield
- RVSB 1.40%
- IKNA N/A
- EPS Growth
- RVSB 27.97
- IKNA N/A
- EPS
- RVSB 0.23
- IKNA N/A
- Revenue
- RVSB $50,239,000.00
- IKNA N/A
- Revenue This Year
- RVSB $12.68
- IKNA N/A
- Revenue Next Year
- RVSB $11.53
- IKNA N/A
- P/E Ratio
- RVSB $24.78
- IKNA N/A
- Revenue Growth
- RVSB 3.95
- IKNA N/A
- 52 Week Low
- RVSB $3.99
- IKNA $0.97
- 52 Week High
- RVSB $6.59
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- RVSB 40.17
- IKNA 56.42
- Support Level
- RVSB $5.65
- IKNA $1.33
- Resistance Level
- RVSB $5.75
- IKNA $1.43
- Average True Range (ATR)
- RVSB 0.13
- IKNA 0.05
- MACD
- RVSB 0.01
- IKNA -0.00
- Stochastic Oscillator
- RVSB 6.02
- IKNA 59.91
About RVSB Riverview Bancorp Inc
Riverview Bancorp Inc is an American savings and loan holding company. The company through its subsidiaries engages in the business of attracting deposits and puts it to use in its market area to originate commercial business. It is organized into two operating segments, Banking Operations performed by the bank and trust and Investment Services performed by the Trust company. The company products and services include checking, saving, money market, mortgage, home equity, consumer, online banking, cash management, and others.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.